Therapeutic Application of Microsponges-based Drug Delivery Systems

Mahfoozur      Rahman; Waleed   H.   Almalki; Sunil   K.   Panda; Aman   K.   Das; Saad      Alghamdi; Kriti      Soni; Abdul      Hafeez; Mayank      Handa; Sarwar      Beg; Ziyaur      Rahman
Abstract

Microsponges delivery systems (MDS) are highly porous, cross-linked polymeric systems that activate due to temperature, pH, or when rubbed. MDS offer a wide range of advantages, like controlled drug release, site-specific action, stability over a broad range of pH, less irritation, cost-effectiveness, and improved patient compliance. They can be transformed into various dosage forms like creams, gels, and lotions. MDS are suitable for the treatment of topical disorders like acne, psoriasis, dandruff, eczema, scleroderma, hair loss, skin cancer, and other dreadful diseases. The applications of MDS in drug delivery are not limited to topical drug delivery but are also explored for oral, parenteral, and pulmonary drug deliveries. Microsponges have been studied for colon targeting of drugs and genes. Additionally, MDS have several applications such as sunscreen, cosmetics, and over-the-counter (OTC) products. Furthermore, MDS do not actuate any irritation, genotoxicity, immunogenicity, or cytotoxicity. Therefore, this review extensively highlights microsponges, their advantages, key factors affecting their characteristics, their therapeutic applications in topical disorders and in cancer, their use as cosmetics, as well as recent advances in MDS and the associated challenges.
Keywords: Microsponges, nanosponges, oral delivery, topical applications, skin irritation, intestinal membrane.
[1] 
Weiss SC. Conventional topical delivery systems. Dermatol Ther  2011; 24(5): 471-6.
[http://dx.doi.org/10.1111/j.1529-8019.2012.01458.x] [PMID:  22353153] 
[2] 
Ingale DJ, Aloorkar NH, Kulkarn IAS, Patil RAP. Microsponges as innovative drug delivery systems. Int J Pharm Sci Nanotechnol  2012; 5(1): 1597-606.
[3] 
Pradhan SK. Microsponges as the versatile tool for drug delivery system. Int J Res Pharm Chem  2011; 1(2): 243-58.
[4] 
Kaity S, Maiti S, Ghosh AK, Pal D, Ghosh A, Banerjee S. Microsponges: A novel strategy for drug delivery system. J Adv Pharm Technol Res  2010; 1(3): 283-90.
[http://dx.doi.org/10.4103/0110-5558.72416] [PMID:  22247859] 
[5] 
Srivastava R, Pathak K. Microsponges: a futuristic approach for oral drug delivery. Expert Opin Drug Deliv  2012; 9(7): 863-78.
[http://dx.doi.org/10.1517/17425247.2012.693072] [PMID:  22663167] 
[6] 
Jadhav N, Patel V, Mungekar S, Bhamare G, Karpe M, Kadams V. Microsponge Delivery System: An updated review, current status and future prospects. J Sci Innov Res  2013; 2(6): 1097-110.
[7] 
Ahire PV, Darekar AB, Saudagar RB. Review on microsponges as a novel drug delivery system. Int J Curr Pharm Rev Res  2017; 8(3): 293-7.
[http://dx.doi.org/10.25258/ijcprr.v8i03.9219] 
[8] 
Kumari P, Mishra SK. A comprehensive review on novel microsponges drug delivery approach. Asian J Pharm Clin Res  2016; 9(1): 25-30.
[9] 
Osmani RA, Aloorkar NH, Kulkarni AS, Harkare BR, Bhosale RR. A new cornucopia in topical drug delivery: Microsponge technology. Asian J Pharm Sci Technol  2014; 4: 48-60.
[10] 
Bharathi M, Mullaikodi O, Rajalingam D, Gnanasekar N, Kesavan M.  Bharathi M, Mullaikodi O, Rajalingam D, Gnanasekar N, Kesavan
M. A review on microsponge drug delivery system. Int J Rev Life
Sci 2020; 10(2): 53-9. Available from: https://scienztech.org/ijrls/article/view/1280
[http://dx.doi.org/10.26452/ijrls.v10i2.1280] 
[11] 
shivajiPatil RuddhavKemkar VPatilSSMicrosponge drug delivery system: A novel dosage form. Am J PharmTech Res  2012; 2(July): 227-51.
[12] 
VISHWAKARMA P Choudhary R. Microsponges: A novel strategy to control the delivery rate of active agents with reduced skin irritancy. J Drug Deliv Ther  2019; 9(6-s): 238-47.
[http://dx.doi.org/10.22270/jddt.v9i6-s.3757] 
[13] 
Aldawsari H. Microsponges as promising vehicle for drug delivery and targeting: Preparation, characterization and applications. Afr J Pharm Pharmacol  2013; 7(17): 873-81.
[http://dx.doi.org/10.5897/AJPP12.1329] 
[14] 
Mahant S, Kumar S, Nanda S, Rao R. Microsponges for dermatological applications: Perspectives and challenges. Asian Journal of Pharmaceutical Sciences  2020; 15(3): 273-91.
[http://dx.doi.org/10.1016/j.ajps.2019.05.004] [PMID:  32636947] 
[15] 
Joshi M. Role of Eudragit in targeted drug delivery. Int J Curr Pharm Res  2013; 5(2): 58-62.
[16] 
Singh S. Neelam , Arora S, Singla Y An overview of multifaceted
significance of eudragit polymers in drug delivery systems Asian
J Pharm Clin Res  2015; 1-6.
[17] 
Obeidat WM, Abu Znait AH, Sallam ASA. Novel combination of anionic and cationic polymethacrylate polymers for sustained release tablet preparation. Drug Dev Ind Pharm  2008; 34(6): 650-60.
[http://dx.doi.org/10.1080/03639040701836578] [PMID:  18568916] 
[18] 
Rekhi GS, Jambhekar SS. Ethylcellulose - A Polymer Review. Drug Dev Ind Pharm  1995; 21(1): 61-77. Available from: http://www.tandfonline.com/doi/full/10.3109/03639049509048096
[http://dx.doi.org/10.3109/03639049509048096] 
[19] 
Ahmadi P, Jahanban-Esfahlan A, Ahmadi A, Tabibiazar M, Mohammadifar M. Development of ethyl cellulose-based formulations: A perspective on the novel technical methods. Food Rev Int  2020; 1-48.
[http://dx.doi.org/10.1080/87559129.2020.1741007] 
[20] 
Li K, Stöver HDH. Synthesis of monodisperse poly(divinyl-benzene) microspheres. J Polym Sci A Polym Chem  1993; 31(13): 3257-63. Available from: https://onlinelibrary.wiley.com/doi/10.1002/pola.1993.080311313
[http://dx.doi.org/10.1002/pola.1993.080311313] 
[21] 
Cong H, Xing J, Ding X, Zhang S, Shen Y, Yu B. Preparation of porous sulfonated poly(styrene-divinylbenzene) microspheres and its application in hydrophilic and chiral separation. Talanta  2020; 210: 120586.
[http://dx.doi.org/10.1016/j.talanta.2019.120586] [PMID:  31987199] 
[22] 
Prajapati SK, Jain A, Jain A, Jain S. Biodegradable polymers and constructs: A novel approach in drug delivery. Eur Polym J  2019; 120: 109191. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0014305719305920
[http://dx.doi.org/10.1016/j.eurpolymj.2019.08.018] 
[23] 
Zhu Y, Shah NH, Malick AW, Infeld MH, McGinity JW. Solid-state plasticization of an acrylic polymer with chlorpheniramine maleate and triethyl citrate. Int J Pharm  2002; 241(2): 301-10.
[http://dx.doi.org/10.1016/S0378-5173(02)00244-2] [PMID:  12100857] 
[24] 
Junqueira MV, Bruschi ML. A review about the drug delivery from microsponges. AAPS PharmSciTech  2018; 19(4): 1501-11.
[http://dx.doi.org/10.1208/s12249-018-0976-5] [PMID:  29484616] 
[25] 
Bae SE, Son JS, Park K, Han DK. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. J Control Release  2009; 133(1): 37-43.
[http://dx.doi.org/10.1016/j.jconrel.2008.09.006] [PMID:  18838089] 
[26] 
Kabiri K, Omidian H, Zohuriaan-Mehr MJ. Novel approach to highly porous superabsorbent hydrogels: Synergistic effect of porogens on porosity and swelling rate. Polym Int  2003; 52(7): 1158-64.
[http://dx.doi.org/10.1002/pi.1218] 
[27] 
Hong Y, Liu X. Pre-gelatinized modification of starch physical modifications of starch.  Singapore: Springer Singapore 2018; pp. 51-61. Available from: http://link.springer.com/10.1007/978-981-13-0725-6_4
[http://dx.doi.org/10.1007/978-981-13-0725-6_4] 
[28] 
Yutani R, Komori Y, Takeuchi A, Teraoka R, Kitagawa S. Prominent efficiency in skin delivery of resveratrol by novel sucrose oleate microemulsion. J Pharm Pharmacol  2016; 68(1): 46-55. Available from: https://academic.oup.com/jpp/article/68/1/46-55/6128296
[http://dx.doi.org/10.1111/jphp.12497] [PMID:  26757020] 
[29] 
Huang B, Aslan E, Jiang Z, et al. Engineered dual-scale poly (ε-caprolactone) scaffolds using 3D printing and rotational electrospinning for bone tissue regeneration. Addit Manuf  2020; 36(February): 101452.
[http://dx.doi.org/10.1016/j.addma.2020.101452] 
[30] 
Pravin Gupta DKMK. Microsponge technology as a versatile drug delivery vehicle Glob J Pharm Educ Res 2017; 6(1-2).
[31] 
Handa M, Tiwari S, Yadav AK, et al. Therapeutic potential of nanoemulsions as feasible wagons for targeting Alzheimer’s disease Drug Discov Today 2021. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1359644621003251
[http://dx.doi.org/10.1016/j.drudis.2021.07.020] 
[32] 
Handa M, Sharma A, Verma RK, Shukla R. Polycaprolactone based nano-carrier for co-administration of moxifloxacin and rutin and its In-vitro evaluation for sepsis. J Drug Deliv Sci Technol  2019; 54(June): 101286.
[http://dx.doi.org/10.1016/j.jddst.2019.101286] 
[33] 
Jain V, Singh R. Dicyclomine-loaded Eudragit®-based microsponge with potential for colonic delivery: preparation and characterization. Trop J Pharm Res  2010; 9(1) Available from: http://www.ajol.info/index.php/tjpr/article/view/52039
[http://dx.doi.org/10.4314/tjpr.v9i1.52039] 
[34] 
Badhe KP, Saudagar RB. A review on microsponge a novel drug delivery system. Asian J Pharm Res  2016; 6(1): 51-7.
[http://dx.doi.org/10.5958/2231-5713.2016.00008.8] 
[35] 
Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Control of prolonged drug release and compression properties of ibuprofen microsponges with acrylic polymer, eudragit rs, by changing their intraparticle porosity. Chem Pharm Bull (Tokyo)  1992; 40(1): 196-201. Available from: http://www.jstage.jst.go.jp/article/cpb1958/40/1/40_1_196/_article
[http://dx.doi.org/10.1248/cpb.40.196] [PMID:  1576674] 
[36] 
Osmani RAM, Aloorkar NH, Thaware BU, Kulkarni PK, Moin A, Hani U, et al. Microsponge based drug delivery system for augmented gastroparesis therapy: Formulation development and evaluation. Asian J Pharm Sci  2015; 10(5): 442-51.
[http://dx.doi.org/10.1016/j.ajps.2015.06.003] 
[37] 
Jyoti J, Kumar S. Innovative and novel strategy: Microsponges for topical drug delivery. J Drug Deliv Ther  2018; 8(5): 28-34. Available from: http://jddtonline.info/index.php/jddt/article/view/1885
[http://dx.doi.org/10.22270/jddt.v8i5.1885] 
[38] 
Parikh BN, Gothi GD, Patel TD, Chavda HV, Patel CN. Microsponge as novel topical drug delivery system. J Glob Pharma Technol  2010; 2(1): 17-29.
[39] 
Akashdeep G, Archana D, Divya J. Microsponges laden gels for topical delivery: A novel approach. Pharma Innov J TPI  2016; 5(6, Part A): 39.
[40] 
Soumya S, Sahu D. A review on novel drug delivery system: Microsponges. Int J Drug Deliv Technol  2017; 7(04): 298-303.
[41] 
Mishra P, Handa M, Ujjwal RR, Singh V, Kesharwani P, Shukla R. Potential of nanoparticulate based delivery systems for effective management of alopecia. Colloids Surf B Biointerfaces  2021; 208: 112050. Available from: https://linkinghub.elsevier.com/retrieve/pii/S092777652100494X
[http://dx.doi.org/10.1016/j.colsurfb.2021.112050] [PMID:  34418723] 
[42] 
Shukla R, Handa M, Pardhi VP. Introduction to Pharmaceutical Product DevelopmentPharmaceutical Drug Product Development and Process Optimization Includes bibliographical references and index.  Apple Academic Press 2020; pp. 1-32. Available from: https://www.taylorfrancis.com/books/9781000731323/chapters/10.1201/9780367821678-1
[http://dx.doi.org/10.1201/9780367821678-1] 
[43] 
Bhatia M, Saini M. Formulation and evaluation of curcumin microsponges for oral and topical drug delivery. Prog Biomater  2018; 7(3): 239-48.
[http://dx.doi.org/10.1007/s40204-018-0099-9] [PMID:  30242738] 
[44] 
Obiedallah MM, Abdel-Mageed AM, Elfaham TH. Ocular administration of acetazolamide microsponges in situ gel formulations. Saudi Pharm J  2018; 26(7): 909-20.
[http://dx.doi.org/10.1016/j.jsps.2018.01.005] [PMID:  30416345] 
[45] 
Castro GA, Ferreira LAM. Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert Opin Drug Deliv  2008; 5(6): 665-79. Available from: http://www.tandfonline.com/doi/full/10.1517/17425247.5.6.665
[http://dx.doi.org/10.1517/17425247.5.6.665] [PMID:  18532922] 
[46] 
Usatine RP, Quan MA. Pearls in the management of acne Prim Care Clin Off Pract 2000; 27(2): 289-308. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0095454305701962
[47] 
Kanlayavattanakul M, Lourith N. Therapeutic agents and herbs in topical application for acne treatment. Int J Cosmet Sci  2011; 33(4): 289-97.
[http://dx.doi.org/10.1111/j.1468-2494.2011.00647.x] [PMID:  21401650] 
[48] 
Krautheim A, Gollnick HPM. Acne: topical treatment. Clin Dermatol  2004; 22(5): 398-407. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0738081X04000422
[http://dx.doi.org/10.1016/j.clindermatol.2004.03.009] [PMID:  15556726] 
[49] 
Jelvehgari M, Siahi-Shadbad MR, Azarmi S, Martin GP, Nokhodchi A. The microsponge delivery system of benzoyl peroxide: preparation, characterization and release studies. Int J Pharm  2006; 308(1-2): 124-32.
[http://dx.doi.org/10.1016/j.ijpharm.2005.11.001] [PMID:  16359833] 
[50] 
Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology  1998; 196(1): 119-25. Available from: https://www.karger.com/Article/FullText/17844
[http://dx.doi.org/10.1159/000017844] [PMID:  9557245] 
[51] 
Osmani RA, Aloorkar NH, Kulkarni AS, et al. Novel cream containing microsponges of anti-acne agent: Formulation development and evaluation. Curr Drug Deliv  2015; 12(5): 504-16.
[http://dx.doi.org/10.2174/1567201812666150212122421] [PMID:  25675339] 
[52] 
Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: A systematic review. J Am Acad Dermatol  2020; 83(1): 151-8.
[http://dx.doi.org/10.1016/j.jaad.2020.03.073] [PMID:  32247872] 
[53] 
Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol  2014; 32(1): 227-55. Available from: https://www.annualreviews.org/doi/10.1146/annurev-immunol-032713-120225
[http://dx.doi.org/10.1146/annurev-immunol-032713-120225] [PMID:  24655295] 
[54] 
Rahman M, Akhter S, Ahmad J, Ahmad MZ, Beg S, Ahmad FJ. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. Expert Opin Drug Deliv  2015; 12(4): 635-52.
[http://dx.doi.org/10.1517/17425247.2015.982088] [PMID:  25439967] 
[55] 
Feldman SR, Horn EJ, Balkrishnan R, et al. International Psoriasis Council. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol  2008; 59(6): 1009-16. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0190962208010700
[http://dx.doi.org/10.1016/j.jaad.2008.08.028] [PMID:  18835062] 
[56] 
Devi N, Kumar S, Prasad M, Rao R. Eudragit RS100 based microsponges for dermal delivery of clobetasol propionate in psoriasis management. J Drug Deliv Sci Technol  2020; 55: 101347.
[http://dx.doi.org/10.1016/j.jddst.2019.101347] 
[57] 
D’auria E, Banderali G, Barberi S, et al. Atopic dermatitis: recent insight on pathogenesis and novel therapeutic target. Asian Pacific J Allergy Immunol  2016; 34(2): 98-108. Available from: http://thailand.digitaljournals.org/index.php/APJAI/article/view/30240
[58] 
Katoh N, Ohya Y, Ikeda M, et al. Committee for clinical practice guidelines for the management of atopic dermatitis 2018, the Japanese society of allergology, the Japanese dermatology association. Japanese guidelines for atopic dermatitis 2020. Allergol Int  2020; 69(3): 356-69.
[http://dx.doi.org/10.1016/j.alit.2020.02.006] [PMID:  32265116] 
[59] 
Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol  2017; 139(6): 1723-34.
[http://dx.doi.org/10.1016/j.jaci.2017.04.004] [PMID:  28583445] 
[60] 
Saini S, Pansare M. New insights and treatments in atopic dermatitis. Pediatr Clin North Am  2021; 41(4): 653-65.
[http://dx.doi.org/10.1016/j.iac.2021.07.005] [PMID:  34602235] 
[61] 
Zaki Rizkalla CM. latif Aziz R, Soliman II. In vitro and in vivo evaluation of hydroxyzine hydrochloride microsponges for topical delivery. AAPS PharmSciTech  2011; 12(3): 989-1001.
[http://dx.doi.org/10.1208/s12249-011-9663-5] [PMID:  21800216] 
[62] 
Pradhan M, Singh D, Murthy SN, Singh MR. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis. Steroids  2015; 101: 56-63.
[http://dx.doi.org/10.1016/j.steroids.2015.05.012] [PMID:  26049018] 
[63] 
D’souza J, More H. Topical anti-inflammatory gels of fluocinolone acetonide entrapped in eudragit based microsponge delivery system. Res J Pharm Technol  2008; 1(4): 502-6.
[64] 
Prakash A, Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs  1998; 55(1): 145-63.
[http://dx.doi.org/10.2165/00003495-199855010-00009] [PMID:  9463794] 
[65] 
Peharda V, Gruber F, Prpić L, Kaštelan M, Brajac I. Comparison of mometasone furoate 0.1% ointment and betamethasone dipropionate 0.05% ointment in the treatment of psoriasis vulgaris. Acta Dermatovenerol Croat  2000; 8(4): 223-6.
[66] 
Rekha U, Manjula BP. Formulation and evaluation of microsponges for topical drug delivery of mometasone furoate. Int J Pharm Pharm Sci  2011; 3(4): 133-7.
[67] 
Sun Q, Leng J, Tang L, Wang L, Fu C. A comprehensive review of the chemistry, pharmacokinetics, pharmacology, clinical applications, adverse events, and quality control of indigo naturalis. Front Pharmacol  2021; 12: 664022. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2021.664022/full
[http://dx.doi.org/10.3389/fphar.2021.664022] [PMID:  34135755] 
[68] 
Hu YS, Han X, Yu PJ, Jiao MM, Liu XH, Shi JB. Novel paeonol derivatives: Design, synthesis and anti-inflammatory activity in vitro and in vivo. Bioorg Chem  2020; 98: 103735. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0045206820301280
[http://dx.doi.org/10.1016/j.bioorg.2020.103735] [PMID:  32171986] 
[69] 
Kumar P, Yadav N, Chaudhary B, et al. Promises of phytochemical based nano drug delivery systems in the management of cancer. Chem Biol Interact  2022; 351: 109745.
[http://dx.doi.org/10.1016/j.cbi.2021.109745]] 
[70] 
Simões MCF, Sousa JJS, Pais AACC. Skin cancer and new treatment perspectives: a review Cancer Lett 2015; 357(1): 8-42. Available from: https://linkinghub.elsevier.com/retrieve/pii/ S0304383514006557
[http://dx.doi.org/10.1016/j.canlet.2014.11.001] [PMID: 25444899] 
[71] 
Bickers DR, Athar M. Novel approaches to chemoprevention of skin cancer. J Dermatol 2000; 27(11): 691-5.  Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1346-8138.2000. tb02259.x
[http://dx.doi.org/10.1111/j.1346-8138.2000.tb02259.x] [PMID: 11138532] 
[72] 
Haque T, Rahman KM, Thurston DE, Hadgraft J, Lane ME. Topical therapies for skin cancer and actinic keratosis. Eur J Pharm Sci  2015; 77: 279-89.
[http://dx.doi.org/10.1016/j.ejps.2015.06.013] [PMID:  26091570] 
[73] 
Korting HC, Schäfer-Korting M. Carriers in the topical treatment of skin disease. Handb Exp Pharmacol  2010; (197): 435-68.
[http://dx.doi.org/10.1007/978-3-642-00477-3_15] [PMID:  20217539] 
[74] 
Jain SK, Kaur M, Kalyani P, Mehra A, Kaur N, Panchal N. Microsponges enriched gel for enhanced topical delivery of 5-fluorouracil. J Microencapsul  2019; 36(7): 677-91.  Available from: https://www.tandfonline.com/doi/full/10.1080/02652048.2019.1667447
[http://dx.doi.org/10.1080/02652048.2019.1667447] [PMID:  31509035] 
[75] 
Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther  2001; 23(6): 908-20.
[http://dx.doi.org/10.1016/S0149-2918(01)80078-3] [PMID:  11440290] 
[76] 
Lochhead RY. Basic physical sciences for the formulation of cosmetic products Cosmetic Science and Technology.  Elsevier 2017; pp. 39-76.  Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780128020050000033
[http://dx.doi.org/10.1016/B978-0-12-802005-0.00003-3] 
[77] 
Wolf R. A glance into the crystal ball: winners and losers in cosmetics. Clin Dermatol  2001; 19(4): 516-23.
[http://dx.doi.org/10.1016/S0738-081X(01)00185-7] [PMID:  11535396] 
[78] 
Katz LM, Dewan K, Bronaugh RL. Nanotechnology in cosmetics. Food Chem Toxicol  2015; 85: 127-37.
[http://dx.doi.org/10.1016/j.fct.2015.06.020] [PMID:  26159063] 
[79] 
Lionetti N, Rigano L. Labeling of cosmetic products. Cosmetics 2018.
[http://dx.doi.org/10.3390/cosmetics5010022] 
[80] 
Rosen MR. Delivery System Handbook for Personal Care and Cosmetic Products: Technology. Applications and Formulations 2005.
[81] 
Kafi R, Kwak HSR, Schumacher WE, et al. Improvement of naturally aged skin with vitamin A (retinol). Arch Dermatol  2007; 143(5): 606-12.
[http://dx.doi.org/10.1001/archderm.143.5.606] [PMID:  17515510] 
[82] 
Bhuptani RS, Patravale VB. Starch microsponges for enhanced retention and efficacy of topical sunscreen. Mater Sci Eng C  2019; 104: 109882.
[http://dx.doi.org/10.1016/j.msec.2019.109882] [PMID:  31500041] 
[83] 
Shukla R, Handa M, Lokesh SB, Ruwali M, Kohli K, Kesharwani P. Conclusion and future prospective of polymeric nanoparticles for cancer therapy Polymeric Nanoparticles as a Promising Tool for Anti-cancer Therapeutics.  Elsevier Inc. 2019; pp. 389-408.
[http://dx.doi.org/10.1016/B978-0-12-816963-6.00018-2] 
[84] 
Gupta A, Tiwari G, Tiwari R, Srivastava R, Rai AK. Enteric coated HPMC capsules plugged with 5-FU loaded microsponges: a potential approach for treatment of colon cancer. Braz J Pharm Sci  2015; 51(3): 591-605.  Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502015000300591& lng=en&tlng=en
[http://dx.doi.org/10.1590/S1984-82502015000300011] 
[85] 
Dhawale SC, Bankar AS, Patro MN. Formulation and evaluation porous microspheres of 5- fluorouracil for colon targeting. Int J Pharm Tech Res 2010.
[86] 
Younis MA, El-Zahry MR, Tallat MA, Tawfeek HM. Sulpiride gastro-retentive floating microsponges; analytical study, in vitro optimization and in vivo characterization. J Drug Target  2020; 28(4): 386-97.
[http://dx.doi.org/10.1080/1061186X.2019.1663526] [PMID:  31478760] 
[87] 
Kasuya F, Igarashi K, Fukui M. Metabolism of chlorpheniramine in rat and human by use of stable isotopes. Xenobiotica  1991; 21(1): 97-109.
[http://dx.doi.org/10.3109/00498259109039454] [PMID:  2003371] 
[88] 
Motov S, Butt M, Masoudi A, et al. Comparison of oral ibuprofen and acetaminophen with either analgesic alone for pediatric emergency department patients with acute pain. J Emerg Med  2020; 58(5): 725-32.  Available from: https://linkinghub.elsevier.com/retrieve/pii/S0736467920301062
[http://dx.doi.org/10.1016/j.jemermed.2020.02.010] [PMID:  32247660] 
[89] 
Devrim B, Canefe K. Preparation and evaluation of modified release ibuprofen microspheres with acrylic polymers (Eudragit) by quasi-emulsion solvent diffusion method: effect of variables. Acta Pol Pharm  2006; 63(6): 521-34.  Available from: http://www.ncbi.nlm.nih.gov/pubmed/17438870
[PMID:  17438870] 
[90] 
Çomoglu T, Gönül N, Baykara T. The effects of pressure and direct compression on tabletting of microsponges. Int J Pharm  2002; 242(1-2): 191-5.  Available from: https://linkinghub.elsevier.com/retrieve/pii/S0378517302001552
[http://dx.doi.org/10.1016/S0378-5173(02)00155-2] [PMID:  12176245] 
[91] 
Comoğlu T, Gönül N, Baykara T. Preparation and in vitro evaluation of modified release ketoprofen microsponges. Farmaco  2003; 58(2): 101-6.
[http://dx.doi.org/10.1016/S0014-827X(02)00007-1] [PMID:  12581775] 
[92] 
Yusuf M, Khan M, Khan RA, Ahmed B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target  2013; 21(3): 300-11.
[http://dx.doi.org/10.3109/1061186X.2012.747529] [PMID:  23231324] 
[93] 
Cui F, Yang M, Jiang Y, et al. Design of sustained-release nitrendipine microspheres having solid dispersion structure by quasi-emulsion solvent diffusion method. J Control Release  2003; 91(3): 375-84.  Available from: https://linkinghub.elsevier.com/retrieve/pii/S016836590300275X
[http://dx.doi.org/10.1016/S0168-3659(03)00275-X] [PMID:  12932715] 
[94] 
Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem  2012; 8(1): 2091-9.
[http://dx.doi.org/10.3762/bjoc.8.235] [PMID:  23243470] 
[95] 
S S S A, Krishnamoorthy K, Rajappan M. Nanosponges: a novel class of drug delivery system--review. J Pharm Pharm Sci  2012; 15(1): 103-11.
[http://dx.doi.org/10.18433/J3K308] [PMID:  22365092] 
[96] 
Cavalli R, Akhter AK, Bisazza A, Giustetto P, Trotta F, Vavia P. Nanosponge formulations as oxygen delivery systems. Int J Pharm  2010; 402(1-2): 254-7.  Available from: https://linkinghub.elsevier.com/retrieve/pii/S037851731000726X
[http://dx.doi.org/10.1016/j.ijpharm.2010.09.025] [PMID:  20888402] 
[97] 
Trotta F, Dianzani C, Caldera F, Mognetti B, Cavalli R. The application of nanosponges to cancer drug delivery. Expert Opin Drug Deliv  2014; 11(6): 931-41.  Available from: http://www.tandfonline.com/doi/full/10.1517/17425247.2014.911729
[http://dx.doi.org/10.1517/17425247.2014.911729] [PMID:  24811423] 
[98] 
Hu SH, Liu TY, Liu DM, Chen SY. Nano-ferrosponges for controlled drug release. J Control Release  2007; 121(3): 181-9.
[http://dx.doi.org/10.1016/j.jconrel.2007.06.002] [PMID:  17644206] 
[99] 
Zhang H, Pan D, Duan X. Synthesis, characterization, and magnetically controlled release behavior of novel core-shell structural magnetic ibuprofen-intercalated LDH nanohybrids. J Phys Chem C  2009; 113(28): 12140-8.  Available from: https://pubs.acs.org/doi/10.1021/jp901060v
[http://dx.doi.org/10.1021/jp901060v] 
[100] 
King CA, Shamshina JL, Zavgorodnya O, Cutfield T, Block LE, Rogers RD. Porous chitin microbeads for more sustainable cosmetics. ACS Sustain Chem& Eng  2017; 5(12): 11660-7.  Available from: https://pubs.acs.org/doi/10.1021/acssuschemeng.7b03053
[http://dx.doi.org/10.1021/acssuschemeng.7b03053] 
[101] 
Shah CN, Shah DP. Microsponges: A revolutionary path breaking modified drug delivery of topical drugs. Int J Pharm Res  2014; 6(2): 1-3.
[102] 
Kumar PM, Ghosh A. Development and evaluation of silver sulfadiazine loaded microsponge based gel for partial thickness (second degree) burn wounds. Eur J Pharm Sci  2017; 96: 243-54.  Available from: https://linkinghub.elsevier.com/retrieve/pii/S0928098716304213
[http://dx.doi.org/10.1016/j.ejps.2016.09.038] [PMID:  27697504] 
[103] 
Arya P, Pathak K. Assessing the viability of microsponges as gastro retentive drug delivery system of curcumin: optimization and pharmacokinetics. Int J Pharm  2014; 460(1-2): 1-12.
[http://dx.doi.org/10.1016/j.ijpharm.2013.10.045] [PMID:  24184218] 
[104] 
Kadhim ZM, Mahmood HS, Alaayedi M, Ghareeb MM. Formulation of flurbiprofen as microsponge drug delivery system Int J Pharm Res 2020; 12(3).
[105] 
Singhvi G, Manchanda P, Hans N, Dubey SK, Gupta G. Microsponge: An emerging drug delivery strategy. Drug Dev Res  2019; 80(2): 200-8. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ddr.21492
[http://dx.doi.org/10.1002/ddr.21492] [PMID:  30456763] 
[106] 
Borawake PD, Kauslya A, Shinde JV, Chavan RS. Microsponge as an emerging technique in novel drug delivery system. J Drug Deliv Ther  2021; 11(1): 171-82.
[http://dx.doi.org/10.22270/jddt.v11i1.4492] 
[107] 
Ambikar RB, Bhosale AV. Formulation and evaluation of eudragit rl100 polymeric drug loaded microsponge for ophthalmic use. J Pharm Res Int 2021; 45-51. Available from: https://www.journaljpri.com/index.php/JPRI/article/view/31440
[http://dx.doi.org/10.9734/jpri/2021/v33i24B31440] 
Cite As
Current Pharmaceutical Design

Therapeutic Application of Microsponges-based Drug Delivery Systems

Abstract
